マクロライド耐性Streptococcus pyogenesの分子疫学および、その抗菌薬感受性と特性 by 田中 悠平
lable at ScienceDirect
J Infect Chemother 22 (2016) 727e732Contents lists avaiJournal of Infection and Chemotherapy
journal homepage: http: / /www.elsevier .com/locate/ j icOriginal ArticleMolecular epidemiology, antimicrobial susceptibility, and
characterization of macrolide-resistant Streptococcus pyogenes
in Japan
Yuhei Tanaka a, Kenji Gotoh a, *, Mariko Teramachi a, Kazuhisa Ishimoto a,
Naoki Tsumura a, Shizuo Shindou b, Yushiro Yamashita a
a Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan
b Shindo Children's Clinic, Fukuoka-shi, Japana r t i c l e i n f o
Article history:
Received 16 March 2016
Received in revised form
24 June 2016
Accepted 30 June 2016
Available online 16 September 2016
Keywords:
Streptococcus pyogenes
Macrolide-resistant
emm typing
MLST
PFGE* Corresponding author. 67 Asahimachi, Kurume
Fax: þ81 942 38 1792.
E-mail address: gotou_kenji@kurume-u.ac.jp (K. G
http://dx.doi.org/10.1016/j.jiac.2016.06.013
1341-321X/© 2016 Japanese Society of Chemotherapy ana b s t r a c t
Here we report the molecular epidemiology of macrolide-resistant Streptococcus pyogenes (group A
streptococci, GAS) isolated from children with pharyngotonsillitis between 2011 and 2013 in Japan. In
299 isolates, 124 (41.5%) isolates were macrolide-resistant. We characterized the isolates by emm typing,
multilocus sequence typing (MLST), and pulsed-field gel electrophoresis (PFGE). Of 299 isolates, 124
(41.5%) were macrolide-resistant isolates, 76 (61.3%) possessed mefA and 46 (37.1%) possessed ermB. All
76 isolates with mefA possessed msrD. There were no isolates possessed ermTR in this study. Eight emm/
MLST types were observed. The predominant type was emm1/ST28 (57 isolates, 46.0%), which possessed
the mefA/msrD complex, presenting as the M phenotype. The second most predominant type was
emm12/ST467, which possessed ermB, presenting as the cMLSB phenotype. Of the cMLSB phenotype
isolates, types emm28/ST52 and emm12/ST36 had multiple genetic backgrounds. We found high pro-
portions of macrolide-resistant GAS in the southwestern areas of Japan.
© 2016 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.1. Introduction
Group A streptococci (GAS) are known to cause awide variety of
human illnesses, including pharyngitis, impetigo, mastoiditis, and
systemic infections, some of which can be life-threatening, such as
sepsis, necrotizing fasciitis, septic arthritis, and toxic shock syn-
drome. In particular, for children, GAS infections are an important
cause of morbidity and mortality worldwide [1,2].
Usually, penicillin is the first choice agent for the treatment of
GAS infections. For severe infections, a combination of high-dose
penicillin and clindamycin is recommended, while for patients
with penicillin allergy, macrolide drugs are recommended as the
first-line therapy. However, a high proportion of macrolide-
resistant GAS (MRGAS) has been reported in many countries that
have not introduced restrictions tomacrolide use. In fact, macrolide
resistance proportions have recently reached 32.8% in Spain, 40% in, Fukuoka 830-0011, Japan.
otoh).
d The Japanese Association for InfectioBelgium, 98.4% in China, and 22.8% in Greece [3e6]. The proportion
of macrolide resistance of GAS is also reportedly high in Japan at
30%e40% [7].
The main macrolide resistance mechanisms of GAS are modifi-
cation of the target site and efflux of macrolide drugs. Several
genes, including ermB, ermA subtype TR (ermTR), mefA, and msrD,
are associated with macrolide resistance [8,9]. ermB and ermTR
encode 23S rRNA methylases which mediate target site modifica-
tion, resulting in antibiotic resistance. These genes lead to resis-
tance to macrolides, lincosamide, and streptogramin B by reducing
the binding ability of these drugs (MLSB phenotype) [9]. mefA and
msrD encode the transmembrane- and ATP-binding domains of
pump that efflux C14 and C15 macrolides out of the cell. The mefA
and msrD genes lead to resistance only to macrolide drugs (M
phenotype) [8].
Among the various virulence factors of GAS that contribute to
successful host invasion, the cell surface M protein plays a key role
in GAS resistance to phagocytosis. The hypervariable 50 region of
the M protein, which is encoded by emm, is further classified by
emm sequence typing [10]. Some studies reported that certain emmus Diseases. Published by Elsevier Ltd. All rights reserved.
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associated with antimicrobial resistance. In addition, emm typing
can vary among regions. Hence, the emm type serves as a useful
marker that is often associated with predominant pathogenic
strains [11].
This study aimed to determine the features of MRGAS isolates
collected from children with pharyngotonsillitis in the south-
western areas of Japan over the past 3 years via emm typing, MLST,
and PFGE. The findings of the present study were compared to
those of a previous Japanese investigation [12] to further elucidate
the mechanism of macrolide resistance of GAS in Japan.
2. Material and methods
2.1. Bacterial isolates
Between 2011 and 2013, a total of 299 GAS isolates were sub-
mitted for characterization to the Department of Pediatrics and
Child Health of Kurume University of Medicine (Kurume, Japan)
from four clinics (Shindo children's clinic, Nagai children's clinic,
Ikezawa children's clinic, and Tsumura clinic) and two general
hospitals (Kurume University Hospital and St. Mary's Hospital) in
the southwestern areas of Japan. These strains were reconstituted
from frozen stocks and propagated on sheep blood agar plates at
37 C. Identification of Streptococcus pyogenes was confirmed by
colony morphology, b-hemolysis on blood agar, the bacitracin test,
the BinaxNOW® Strep A test (Alere Medical Co., Ltd., Chiba, Japan),
and 16S rRNA polymerase chain reaction (PCR) analysis [8]. A total
of 124 erythromycin-resistant isolates collected from patients with
pharyngotonsillitis was selected for analysis (see the Antimicrobial
susceptibility test section).
2.2. Antimicrobial susceptibility test
Minimum inhibitory concentrations (MICs) were determined
using the broth dilution method performed in accordance with the
guidelines of the Clinical and Laboratory Standards Institute (CLSI).
The reference strain Streptococcus pneumoniae ATCC 49619 was
included as a control. GAS strains were tested against 6 antibiotics:
penicillin G (Meiji Seika Pharma Co., Ltd., Tokyo, Japan), amoxicillin
(SigmaeAldrich Co., LLC, Tokyo, Japan), erythromycin (Dainippon
Pharmaceutical Co., Ltd., Osaka, Japan), clarithromycin (Taisho
Pharmaceutical Co., Ltd., Osaka, Japan), azithromycin (Pfizer Japan
Inc., Tokyo, Japan), and clindamycin (Pfizer Japan Inc.). Suscepti-
bility results were categorized according to the CLSI criteria [13].
The erythromycin-resistant (MIC  1 mg/ml) isolates were then
selected as the study population.
2.3. Determination of macrolide-resistant phenotypes
The clindamycin-susceptible and erythromycin-resistant iso-
lates were classified as phenotype M using the disk diffusion sus-
ceptibility test, which was performed in accordance with the CLSI
recommendations [13]. Among the erythromycin-resistant strains,
resistant phenotype patterns were classified as clindamycin-
susceptible (M phenotype), -resistant (constitutive phenotype,
cMLSB), or -inducible (inducible phenotype, iMLSB) [14].
2.4. Detection of erythromycin-resistant genes
All erythromycin-resistant isolates were screened by PCR for the
erythromycin-resistance genes ermB, ermA, mefA, and msrD. PCR
assays were performed according to previously described condi-
tions for each individual primer pair [8,15,16].2.5. T-serotype and emm type (emm/T types)
The T-serotype was identified using a slide agglutination test
with type-specific antisera (DENKA SEIKEN Co., Ltd, Tokyo, Japan).
emm sequencing was performed in accordance with the protocol of
the CDC International Streptococcal Reference Laboratory (http://
www.cdc.gov/streplab/M-ProteinGene-typing.html).2.6. PFGE analysis
PFGE analysis was performed as previously described, with
slight modifications [17]. In brief, chromosomal DNA was digested
overnight at 30 C with the restriction enzyme SgrAI (New England
biolabs Japan Inc., Tokyo, Japan). The electrophoresis conditions
were 22 h with 0.5e40 s switch time ramp at a 120 angle and 6 V/
cm using a CHEF Mapper system (Bio-Rad Laboratories, Inc., Her-
cules, CA, USA). The DNA bands were stained with ethidium bro-
mide and photographed. The interpretation of PFGE patterns was
based on criteria described by Tenover et al. [18]. SgrAI profiles
were coded alphabetically, and for closely related pulsotypes (dif-
ferences in 2 or 3 bands), a number was added. PFGE profiles were
analyzed using Quantity One® software version 4.6.3 (Bio-Rad
Laboratories, Inc.), employing the unweighted pair group method
with arithmetic mean with the Dice coefficient and a position
tolerance of 1% [19].2.7. MLST analysis
All macrolide-resistant isolates, which included nearly every
emm type and PFGE cluster, were assessed by MLST in accordance
with the protocol on the MLST website. The primers of 7 house-
keeping genes (i.e., gki, gtr, muri, mutS, recP, xpt, and yiqL) were
based on information from the MLST website [20]. The allele and
sequence type were assigned using the MLST websites.2.8. Ethical statement
An ethical approval or patients' consent was not required since
the study only includes microbiological samples sent to Depart-
ment of Pediatrics and Child Health, Kurume University School of
Medicine on an anonymized basis and did not involve human
subjects or material, and patients could not be identified.3. Results
3.1. Antimicrobial susceptibility
A total of 299 GAS isolates were collected between 2011 and
2013, which included 84, 149, and 66 isolates collected in 2011,
2012, and 2013, respectively. All 299 GAS isolates showed suscep-
tibility to penicillin G and amoxicillin. Of the 299 GAS isolates, 124
(41.5%) were erythromycin-resistant, including 44 (52.4%), 54
(36.2%), and 26 (39.4%) collected in 2011, 2012, and 2013, respec-
tively. The proportions of resistance to clarithromycin, azi-
thromycin, and clindamycin were 41.5%, 42.8%, and 16.4%,
respectively. A total of 101 isolates (33.8%) were highly resistant to
erythromycin (MIC  16 mg/ml). Of the 299 GAS isolates, MIC50/90
values for erythromycin were 0.25/128 mg/ml (Table 1). None of
the erythromycin-resistant isolates were susceptible to clari-
thromycin or azithromycin, whereas 73 erythromycin-resistant
isolates were susceptible to clindamycin.
Table 1
Antimicrobial susceptibilities of GAS isolates from 2011 to 2013.
Agent 2011e2013 (n ¼ 299) (mg/ml) % resistance, by year
Range MIC50 MIC90 2011 (n ¼ 84) 2012 (n ¼ 149) 2013 (n ¼ 66)
Erythromycin 0.063e128 0.25 128 52.4 36.2 39.4
Clarithromycin 0.063e128 0.25 128 52.4 36.2 39.4
Azithromycin 0.063e128 0.5 128 54.8 36.2 42.4
Clindamycin 0.063e128 0.125 128 17.9 14.8 19.7
No resistance was found to penicillin G and amoxicillin.
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Of the 124 erythromycin-resistant isolates, 76 were classified as
phenotype M and 48 were classified as phenotype cMLSB. There
were no iMLSB isolates in this study. For all the M phenotype iso-
lates, MIC50 of erythromycin was 16 mg/ml and that of clindamycin
was 0.125 mg/ml. For all the cMLSB phenotype isolates, MIC50 of
erythromycinwas 128 mg/ml and that of clindamycinwas 128 mg/ml
(Table 2).3.3. Detection of erythromycin-resistant genes
Among the macrolide-resistant isolates, 76 (61.3%) possessed
mefA and 46 (37.1%) possessed ermB. All the isolates possessing
mefA also possessed msrD. No isolate possessed both mefA and
ermB, and no strain possessed ermTR. In this study, no resistance
genes were found in 2 isolates. The MIC90 values formefA/msrD and
ermB were 16 and 128 mg/ml, respectively. MIC for each of the 45
isolates (97.8%) positive for ermB was 128 mg/ml. All strains that
possessed ermB were classified as phenotype cMLSB (Table 2).3.4. T-serotype and emm type (emm/T types)
Ten emm/T types were detected among all macrolide-resistant
isolates (Table 3). The predominant emm/T types were emm1/T1
(57 isolates, 46.0%), followed by emm12/T12 (46 isolates, 37.1%),
emm28/T28 (7 isolates, 5.6%), emm170/T25 (7 isolates, 5.6%),
emm75/T25 (2 isolates, 1.6%), emm75/T4 (1 isolate, 0.8%), emm89/T
B3264 (1 isolate, 0.8%), emm170/T5/27/44 (1 isolate, 0.8%), emm4/
T4 (1 isolate, 0.8%), and emm12/NT (1 isolate, 0.8%). Of these emm/T
types, macrolide resistance was particularly high for the emm12/
T12 type with MIC50 for erythromycin of 128 mg/ml. The re-
lationships between macrolide-resistant genes and emm/T types
are shown in Table 3. ermB was detected in types emm12 and
emm28. The mefA/msrD complex was detected in types emm1,
emm12, emm4, emm75, and emm170.Table 2
Distribution of MICs, phenotype, and genotypes of erythromycin-resistant genes (n ¼ 12
Phenotype No. of isolates Antimicrobial agent (mg/ml) E
Range MIC50 MIC90 m
2
M 76 EM 8e32 16 32 3
CLDM 0.063e1 0.125 0.25
cMLSB 48 EM 64e128 128 128 0
CLDM 64e128 128 128
iMLSB 0 EM e ND ND 0
CLDM e ND ND
3
Total 124 EM 8e128 16 128 7
CLDM 0.063e128 128 128
The isolates of 76 strains possessed both the mefA genes andmsrD genes. In this study, w
There were no isolates which possessed mef A and ermB together. None of isolate posse3.5. MLST, emm typing, and PFGE
All macrolide-resistant isolates were subjected to MLST, which
revealed the presence of 7 different sequence types: ST28, ST36,
ST38, ST49, ST52, ST467, and ST646. Finally, 8 emm/MLST types
were observed in this study population. The predominant emm/
MLST types were emm1/ST28 (57 isolates, 46.0%), followed by
emm12/ST467 (24 isolates, 19.4%), emm12/ST36 (23 isolates, 18.5%),
emm170/ST49 (8 isolates, 6.5%), emm28/ST52 (7 isolates, 5.6%),
emm75/ST49 (3 isolates, 2.4%), emm89/ST646 (1 isolate, 0.8%), and
emm4/ST38 (1 isolate, 0.8%) (Table 3).
All 124 isolates were subjected to PFGE using the restriction
enzyme SgrAI. All the 124 SgrAI-digested macrolide-resistant iso-
lates were assigned to 12 pulsotypes: A (57 isolates: 46.0%), B (24
isolates: 19.3%), C (11 isolates: 8.9%), D (9 isolates: 7.3%), E (7 iso-
lates: 5.6%), F (5 isolates: 4.0%), G (5 isolates: 4.0%), H (2 isolates:
1.6%), I (1 isolate: 0.8%), J (1 isolate: 0.8%), K (1 isolate: 0.8%), and L
(1 isolate: 0.8%).
PFGE, emm typing, and MLST results showed that most GAS
isolates in the same PFGE pulsotype were the same emm and MLST
types. In the pulsotype C group, there were 2 emm types: emm75
and emm170. The most predominant pulsotype was A/emm1/ST28
(57 strains: 46.0%), which possessed the mefA/msrD complex. The
next most common pulsotype was B/emm12/ST467 (24 strains,
19.3%), which possessed ermB. The relationships between the PFGE
pulsotype and emm/ST types are shown in (Fig. 1).
There is no statistical difference against a certain emm/ST/PFGE
type to macrolide-resistant proportion by year. The statistical
analysis was performed according to the chi-square test.4. Discussion
The prevalence of MRGAS was approximately <10% before 2000
[21], but it has gradually increased each year since then, and recent
studies have reported that the prevalence of MRGAS is 30%e40% in
Japan [7]. However, details regarding macrolide-resistant4).
rythromycin-resistant genes (no. of isolates)
efA ermB msrD
011 2012 2013 2011 2012 2013 2011 2012 2013
1 32 13 0 0 0 31 32 13
0 0 11 22 13 0 0 0
0 0 0 0 0 0 0 0
1 32 13 11 22 13 31 32 13
6 46 76
e found no isolates that possessed ermTR genes. All but 2 isolates hadmefA or ermB.
ssed ermTR.
Table 3
Distribution of emm/T types/MLST, genes, and erythromycin-resistant isolates (n ¼ 124).
emm type T type MLST type No. of isolates Genes (no. of isolates) MIC50 of EM (mg/ml)
mefA ermB msrD
emm1 T1 ST28 57 57 0 57 16
emm4 T4 ST38 1 1 0 1 8
emm12 T12 ST36/ST467 46 7 38 7 128
emm12 NT ST467 1 0 1 0 128
emm28 T28 ST52 7 0 7 0 128
emm75 T4 ST49 1 1 0 1 16
emm75 T25 ST49 2 2 0 2 16
emm89 TB3264 ST646 1 0 0 0 128
emm170 T25 ST49 7 7 0 7 16
emm170 T5/27/44 ST49 1 1 0 1 8
Total 124 76 46 76
Fig. 1. Dendrogram and PFGE patterns of SgrAI-digested chromosomal DNA, and association with phenotype, emm type, sequence type, and isolation year in erythromycin-resistant
GAS (n ¼ 124). DNA size standards (lambda ladder; 50e1000 kb). SgrAI-digested isolates generated 12 pulsotypes (AeL) and closely related pulsotypes (differences in 2 or 3 bands)
were assigned to each PFGE clusters (A, E, F). NT: nontypeable.
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these past reports. The purpose of this study was to survey the
genetic diversity of pharyngeal GAS isolates by T typing, emm
typing, MLST, and PFGE to identify factors related to the high pro-
portion of macrolide resistance of GAS in Japan and to further
elucidate the epidemiology of MRGAS.
The proportion of macrolide resistance varies by country. For
example, among Asian countries, the incidence of macrolide
resistance in Korea and Taiwan has decreased [22,23], but it has
remained relatively high in China [4,24]. In European countries, the
incidence of macrolide resistance has reportedly decreased inGermany and France [25]. The results of the present study showed
that the proportion of MRGAS remained at >40%. Of all macrolide-
resistant isolates included in this study, 61.3% were classified as
phenotype M and 38.7% as phenotype cMLSB. The proportions of
these resistance phenotypes were similar to those observed within
other East Asian countries.
The GAS Surveillance Study Group in Japan reported that the
most prevalent emm type of MRGAS was emm1, followed by emm12
and emm28. Each of these 3 emm types had high proportions of
macrolide resistance (64.3%e87.2%) [26]. In our study, the most
prevalent emm types of the MRGAS were emm1, emm12, and
Y. Tanaka et al. / J Infect Chemother 22 (2016) 727e732 731emm28. The emm12 and emm4 types are reportedly the most
common in various countries, while emm4 strains were the most
predominant among MRGAS, particularly in Europe [25,28].
Of theM phenotype isolates, therewere 5 emm/ST types (emm1/
ST28, emm75/ST49, emm170/ST49, emm12/ST36, and emm4/ST38)
and 4 PFGE pulsotypes (A, C, E, and I). emm1/ST28 was the most
prevalent in our study. The domestic surveillance results showed
that the predominant emm1 types among the MRGAS were ST28
and ST661 [26]. In our study, emm1/ST28 was also the most pre-
dominant type, suggesting that this type was the most prevalent
genotype among pharyngotonsillitis cases over the past several
years in Japan. With regard to the PFGE band patterns, emm1/ST28
had only 1 pulsotype (pulsotype A), which revealed that the most
prevalentMRGAS type. emm1/ST28 had the same genetic homology
and macrolide resistance was mainly related to the prevalence of
this type clones in Japan. Of the macrolide-resistant proportions by
year, the highest proportion of macrolide-resistance was observed
in 2011. In this study we could not find the relationship of a certain
emm/ST/PFGE type with macrolide-resistant proportion. Therefore,
it could be suggested that there was no outbreak by a certain emm/
ST/PFGE type of MRGAS in the southwestern areas of Japan.
Although individual emm types were associated with multiple
PFGE patterns, emm75 and emm st1815 (emm170) shared the same
PFGE type. The emm sequence st1815 (emm170) was likely gener-
ated by homologous excision between tandem emm and enn se-
quences in an emm75 parental strain, as suggested in the emm
sequence database (http://www.cdc.gov/streplab/types-emm103-
124.html).
Among the isolates with the cMLSB phenotype, there were 4
emm/ST types (emm12/ST467, emm12/ST36, emm28/ST52, and
emm89/ST646) and 9 PFGE pulsotypes (B, D, E, F, G, H, J, K, and L).
emm12/ST467 was the most prevalent in our study. emm12 type
ST465 or ST36 was the most prevalent in a previous Japanese
investigation between April and October 2012 [26], whereas
emm12/ST467 (19.4%, 24/124 strains) rather than emm12/ST36
(18.5%, 23/124 strains) was the most prevalent in our study. We
suggested that one of the reasons for the difference in these two
studies was the period of investigation. Their study period was
short; therefore, their investigation may not exactly express the
prevalence situation of emm/ST type, and our investigation could
not be compared the previous abovementioned investigation.
ST465 and ST467 are single-locus variants of ST36. The results of
these two studies indicate that the clonal variant emm12/ST36 was
widespread in Japan.
Studies conducted in Europe and East Asia reported that emm12
strains were the most predominant among MRGAS [27,30]. With
regard to the PFGE band patterns, emm12/ST467 was clustered into
1 PFGE pattern (pulsotype B) and emm12/ST36 was clustered into 4
patterns (pulsotypes D, E, G, and H), which had significantly
different patterns from pulsotype B. To our knowledge, this is the
first report to reveal that emm12/ST467 is one of the predominant
types of MRGAS in Japan. Our findings suggest that emm12/ST467 is
a novel MRGAS in East Asian countries, including Japan.
Several studies have reported a statistically significant associa-
tion between macrolide resistance and emm28 [29,32], and most
emm28 strains had the ermB gene [31]. Although few articles have
reported the distribution of emm28 in other Asian countries, in our
study, 7 of 124 strains were identified as emm28/ST52, and all
possessed the ermB gene. This finding suggests that the charac-
teristics of emm28 are the same worldwide. The prevalence of
emm28 increased throughout this study period and, thus, may be
associated with an increase in MRGAS detection.
Several studies have reported correlations between the increase
in MRGAS prevalence and macrolide use [33e35]. In response,
some countries have started restricting the use of some antibiotics,including macrolides and decreased the proportion of MRGAS
[29,33]. These reports showed antimicrobial stewardship including
restriction of macrolide drugs lead decreasing proportion of
MRGAS. However, some anti-inflammatory effects have been re-
ported for a 14-member macrolide drug used [36]. Macrolide drugs
are often used inadequately for the treatment of respiratory in-
fections such as those caused by influenza virus in Japan. This
phenomenon is in contrast to the global situation, which may be
one of the reasons why the proportion of macrolide resistance has
remained greater than 40%.
In this study we investigated the typing among only macrolide-
resistant strains, therefore we could not indicate the relationship
between macrolide-resistant proportions and typing such as emm
typing and MLST among whole strains included macrolide-
susceptible strains. In further investigations, we need to analysis
the typing of all provided isolates, and investigate for more wide
area to determine the feature of GAS isolates exactly.
In summary, we found high proportions of MRGAS and the
prevalence of 2 predominant genotypes (emm1/ST28 and emm12/
ST467) in Japan.
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